CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
November 20 2019 - 9:18PM
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company
focused on developing transformative gene-based medicines for
serious diseases, today announced the pricing of an underwritten
public offering of 4,250,000 common shares at a public offering
price of $64.50 per share. In addition, the underwriters have a
30-day option to purchase up to an additional 637,500 common shares
at the public offering price less the underwriting discount. CRISPR
Therapeutics anticipates its gross proceeds from the offering,
before deducting underwriting discounts and commissions and other
offering expenses, to be approximately $274.1 million, excluding
any exercise of the underwriters’ option to purchase additional
shares. The offering is expected to close on or about November 25,
2019, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Piper Jaffray & Co. and
Jefferies LLC are acting as joint book-running managers for the
offering. Chardan, Oppenheimer & Co. Inc., BTIG, LLC and Roth
Capital Partners are acting as co-managers for the offering.
The common shares will be offered and sold pursuant to the
Company’s previously filed automatically effective shelf
registration statement on Form S-3 (File No. 333-227427) filed with
the U.S. Securities and Exchange Commission (the “SEC”) on
September 19, 2018. This press release shall not constitute an
offer to sell or a solicitation of an offer to buy, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
A preliminary prospectus supplement relating to and describing
the terms of the offering was filed with the SEC on November 19,
2019. The final prospectus supplement relating to the offering will
be filed with the SEC and will be available on the SEC’s website at
www.sec.gov. A copy of the final prospectus supplement may be
obtained, when available, from Goldman Sachs & Co. LLC by mail
at 200 West Street, New York, NY 10282, Attention: Prospectus
Department, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; from Piper Jaffray & Co., Attn:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924, or by email at
prospectus@pjc.com; or from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at (877) 547-6340, or by email at
prospectus_department@jefferies.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR Therapeutics AG
is headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in London, United
Kingdom.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding CRISPR Therapeutics’ anticipated public offering. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, such as the expected closing date, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions and the satisfaction of customary closing
conditions related to the offering. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in CRISPR Therapeutics’ Annual Report on
Form 10-K for the year ended December 31, 2018, as filed with the
SEC on February 25, 2019, the prospectus supplement related to the
public offering and other filings that CRISPR Therapeutics may make
with the SEC in the future. Any forward-looking statements
contained in this press release represent CRISPR Therapeutics’
views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. CRISPR
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
Investor Contact:Susan Kimsusan.kim@crisprtx.com
Media Contact:Jennifer PaganelliWCG on behalf of
CRISPR347-658-8290jpaganelli@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024